A 52-year-old man with metastatic adenocarcinoma of the pancreas presents with acute dyspnea and chest pain. Examination reveals petechiae on the lower extremities and oozing from venipuncture sites. Laboratory results: Hb 9.8 g/dL, WBC 7,200/μL, platelet count 42,000/μL, PT 22 seconds (control 13), aPTT 58 seconds (control 36), fibrinogen 110 mg/dL (normal 200–400), D-dimer 6.2 μg/mL (normal <0.5), LDH 580 U/L, creatinine 1.8 mg/dL. Chest X-ray shows bilateral pulmonary infiltrates. What is the most appropriate next step in management?

Explanation

## Management of DIC in Malignancy ### Clinical Diagnosis: DIC Secondary to Metastatic Pancreatic Adenocarcinoma This patient meets ISTH criteria for **overt DIC**: | Parameter | Finding | Points | |-----------|---------|--------| | Platelet count | 42,000/μL (< 50,000) | 1 | | D-dimer/FDP | 6.2 μg/mL (markedly elevated) | 3 | | PT prolongation | 22 sec (9 sec above control) | 1 | | Fibrinogen | 110 mg/dL (< 100) | 1 | | **Total** | | **≥ 5 = Overt DIC** | The clinical presentation (bleeding, petechiae, pulmonary infiltrates, organ dysfunction) confirms **acute DIC**. ### Pathophysiology: Cancer-Induced DIC **Key Point:** Solid tumors (especially adenocarcinomas) trigger DIC via: 1. **Tissue Factor (TF) expression** — Cancer cells express TF on their surface. 2. **Cancer procoagulant** — Direct Factor X activation independent of Factor VII. 3. **Cytokine release** — IL-1, TNF-α, IL-6 → endothelial activation → TF upregulation. 4. **Phosphatidylserine exposure** — Apoptotic tumor cells expose PS, a potent coagulation trigger. Pancreatic adenocarcinoma is particularly thrombogenic due to high TF expression. ### Management Algorithm for DIC ```mermaid flowchart TD A["Overt DIC Diagnosed<br/>(ISTH score ≥5)"]:::outcome --> B{"Bleeding or<br/>Thrombotic?"} B -->|"Bleeding<br/>(most common)"| C["Supportive Transfusion"] C --> C1["FFP for fibrinogen<br/>Platelet transfusion<br/>RBC transfusion as needed"]:::action B -->|"Thrombotic<br/>(rare)"| D["Anticoagulation"] D --> D1["Heparin (if no bleeding)"]:::action C1 --> E["Treat Underlying Cause"]:::action D1 --> E E --> E1["Chemotherapy for cancer<br/>ATRA/ATO for APL<br/>Antibiotics for sepsis"]:::action E1 --> F["Monitor: Repeat labs q6-12h"]:::action F --> G{"DIC Resolving?"} G -->|"Yes"| H["Continue supportive care<br/>Taper transfusions"]:::outcome G -->|"No"| I["Reassess underlying disease<br/>Consider ICU monitoring"]:::urgent ``` ### Why NOT Heparin (Option 0)? **Warning:** Heparin is **contraindicated in bleeding-predominant DIC** (which this patient has): - Patient is actively bleeding (petechiae, venipuncture oozing). - Heparin increases bleeding risk in the setting of low fibrinogen and thrombocytopenia. - Heparin is reserved for **thrombotic DIC** (rare, e.g., acute promyelocytic leukemia with thrombosis), where thrombosis predominates over bleeding. **Clinical Pearl:** The rule is: - **Bleeding DIC** → Transfusion support (FFP, platelets, RBC) - **Thrombotic DIC** → Anticoagulation (heparin) This patient has **bleeding DIC**, so heparin is wrong. ### Correct Management: Supportive Transfusion + Treat Underlying Disease **High-Yield:** The management triad for cancer-induced DIC: 1. **Immediate Supportive Care** - **FFP** — Replace consumed fibrinogen and clotting factors. Target fibrinogen >100 mg/dL (transfuse 10–15 mL/kg FFP). - **Platelet transfusion** — Target >20,000–30,000/μL if bleeding; >50,000/μL if invasive procedure planned. - **RBC transfusion** — Maintain Hb >7 g/dL (higher if active bleeding or cardiopulmonary compromise). - **Avoid diuretics** — Do not worsen hypovolemia. 2. **Definitive Treatment: Address the Underlying Cancer** - Initiate **chemotherapy** (e.g., gemcitabine + cisplatin for pancreatic adenocarcinoma). - DIC often **reverses within 24–48 hours** of effective cancer treatment as TF-expressing tumor cells are killed. 3. **Monitoring** - Repeat coagulation studies (PT, aPTT, fibrinogen, D-dimer, platelet count) every 6–12 hours. - Assess for organ dysfunction (renal, hepatic, pulmonary). - ICU monitoring if severe or multiorgan involvement. **Key Point:** In cancer-induced DIC, **treating the cancer is curative for DIC**. Supportive transfusion buys time until chemotherapy takes effect. ### Why the Other Options Are Wrong **Option 2 (Intubation):** While the patient has dyspnea and pulmonary infiltrates (likely DIC-induced acute lung injury), intubation is not the "next step." Supportive care and cancer treatment address the root cause. Intubation may be needed later if respiratory failure worsens despite treatment, but it is not the immediate next step. **Option 3 (Aspirin):** Aspirin has no role in DIC management. It does not address the consumption coagulopathy and may worsen bleeding. ### Why This Question Is High-Yield **High-Yield:** NEET PG examiners test: - Recognition of DIC in malignancy (especially adenocarcinomas). - The distinction between **bleeding DIC** (transfusion) vs. **thrombotic DIC** (heparin). - Understanding that **treating the underlying disease is key** to DIC resolution. - Avoidance of heparin in bleeding DIC (a common trap). [cite:Robbins 10e Ch 13; Harrison 21e Ch 110; Lichtman's Atlas of Hematology Ch 45]